No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...

We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

The Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...

Bio Asia 2025 will feature high-impact sessions, panel discussions, and networking opportunities, engaging thought leaders, ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Out-of-pocket costs like deductibles and copays deter people with cancer from complying with treatment.This creates a ...

"Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc ...

The Trump administration is moving forward with the defense of a Biden-era plan that allows Medicare to negotiate drug prices ...

Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...